Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint Inhibitors.

Camila B. Xavier, M.D.[1,#], Carlos Diego H. Lopes, M.D.[1], Beatriz M. Awni, M.D.[1], Eduardo F. Campos, M.D.[1], João Pedro B. Alves[2], Anamaria A. Camargo, PhD[3], Gabriela D. A. Guardia, Ph.D.[3], Pedro A. F. Galante, Ph.D.[3,#] and Denis L. Jardim, M.D., Ph.D.[1,#]

1- Oncology Center, Sirio-Libanes Hospital, Sao Paulo, Brazil
2- Falconi Consultants for Results, Sao Paulo, Brazil
3- Molecular Oncology Center - Instituto de Ensino e Pesquisa, Sirio-Libanes Hospital, Sao Paulo, Brazil

Keywords: Tumor mutation burden; immune Checkpoint inhibitors; immunotherapy

Corresponding authors:
Camila Bragança Xavier, M.D.
Sirio Libanês Hospital
115, Dona Adma Jafet, Second floor, building A
01308-050. São Paulo, SP, Brazil
Phone number: +55 11 972544896
Email: camilabragancamed@gmail.com

Denis L Jardim, MD, PhD
Sirio Libanês Hospital
115, Dona Adma Jafet, Second floor, building A
01308-050. São Paulo, SP, Brazil
Phone number: +55 11 997072594
Email: jardimde@gmail.com

Pedro A. F. Galante, Ph.D
Sirio Libanês Hospital
69, Daher Cutait.
01308-050. São Paulo, SP, Brazil
Phone number: +55 11 3394-4167

Email: pgalante@mochsl.org.br

Word count: Abstract 346; Manuscript 1,277
Figure/Table count: 3
Reference count: 13

KEY POINTS

Question. Can we improve response prediction to ICI treatment by assessing tumor mutational burden (TMB) and other molecular or clinical variables from cancer patients?

Findings. In this study we found that somatic mutation profile can modify responses to ICIs in patients with TMB ≥ 10 mut/Mb. Conversely, other variables such as MSI status, age or gender were found to not be important in predicting response to ICI treatment.

Meaning. While prospective trials are still required, we found that combination of a high TMB and somatic mutational profile in key cancer genes can be used to better select patients for ICI treatment.

ABSTRACT

Importance: Tumor mutational burden (TMB) greater than or equal to 10 mutations per megabase (mut/Mb) has received agnostic FDA approval for pembrolizumab. However, this TMB cut-off alone is not a complete predictor of overall survival (OS) in patients treated with immune checkpoint inhibitors (ICIs).

Objective. To analyze the influence of the molecular profile in patients with TMB ≥ 10mut/Mb treated with ICIs.

Design, Setting, and Participants. This post-hoc analysis evaluated the clinical and molecular features of tumor-normal pairs from 1,661 patients with solid tumors sequenced using the MSK-IMPACT assay and treated with ICIs.

Main Outcomes and Measures. We performed OS analysis and compared the results for TMB thresholds of ≥ 10, ≥ 20, and < 10 mut/Mb. For a TMB ≥ 10mut/Mb, we assessed OS according to mutational status. For all genes exhibiting a correlation with OS ($P < 0.05$), we conducted a Cox multivariate analysis adjusted by median TMB, sex, median age, microsatellite instability (MSI) status, and histology.

Results. After a maximum follow-up of 80 months, a total of 1,661 patients were investigated, and survival to ICIs increased with higher TMB cut-offs. The median OS was 42 months for TMB ≥ 10 or 20mut/Mb, and 15 months for TMB < 10 mut/Mb ($P < 0.005$). Patients harboring a TMB ≥ 10 (N=488, 29%) were further stratified by their somatic mutation profile in key cancer genes. When only genes with n ≥ 5 patients were considered, mutations in *E2F3* or *STK11* were correlated with worse OS, and those with mutations in *NTRK3, PTPRD, RNF43, TENT5C, TET1* or *ZFHX3* were correlated with better OS in TMB-high patients

receiving ICIs compared to wild-type patients. These associations were confirmed by univariate and multivariate analyses ($P < 0.05$). MSI status and clinical features, including age, sex, and histology (except for melanoma), failed to predict outcomes to ICIs in patients with high TMB.

Conclusion and relevance. The findings suggest that combining TMB information and mutation profiles in key cancer genes can be used to better qualify patients for ICI treatment and predict their OS.

INTRODUCTION

Tumor mutational burden (TMB) has been correlated with the response to immune checkpoint inhibitors (ICIs) in a retrospective cohort including 1,661 patients treated with ICIs. Among all patients, higher somatic TMB, defined as the highest (20%) in histology, was a predictor of better overall survival (OS)[1]. Subsequently, a prospective analysis from the phase II KEYNOTE-158 trial stated that a TMB of at least 10 somatic tumor mutations per megabase (mut/Mb) was associated with a higher proportion of objective response rates (ORR) to pembrolizumab monotherapy[2]. These results led to the FDA agnostic approval of pembrolizumab for TMB-high (≥ 10mut/Mb) patients. Notably, 42% of patients presenting with high TMB do not respond to ICIs;

other clinical and molecular factors may have important roles in modulating the tumor response to ICIs[3]. To better qualify patients with TMB ≥ 10 mut/mB for ICI treatment, we investigated their mutation profiles and correlated them with their survival outcomes.

METHODS

Study Design

We collected genomic and survival data from 1,661 patients[1,4] and retrieved their mutation profiles (MSK-IMPACT). This assay identifies somatic exonic mutations in a predefined subset of 468 cancer-related genes (earlier versions included 341 or 410 genes), by using both tumor-derived and matched germline normal DNA. TMB was determined by the number of nonsynonymous somatic mutations.

Statistical Analysis

Overall survival (OS) for all patients who received at least one dose of ICIs was estimated using the Kaplan-Meier method. The Cox regression model was used to define the hazard ratios (HRs) for death, and a log-rank test was used to compare the results (95% confidence intervals for all analyses). The Python Lifelines package (version 0.26.4)[5] was used for Kaplan–Meier and Cox analyses. A validation analysis correlated

predefined percentiles used in the original publication[2] with absolute cut-off values. For a ≥ 10mut/Mb cutoff, we assessed OS regarding the mutational status of each gene mutation with n > 5 patients (N = 392).

For all genes exhibiting a correlation with survival considering an alpha-error level ($P < 0.05$), a Cox multivariate analysis was also conducted using Reboot[6]. The adjustment variables included sex, median age, microsatellite instability (MSI) status, TMB under or above the median TMB of the cohort (20 mut/Mb), and histology (non-small cell lung cancer (NSCLC), melanoma, bladder cancer, and colorectal cancer). Since MSI status was not available in the current database, an individual assessment of somatic mutations in *MLH1, MSH2, MSH6, PMS2*, and *SETD2* was used as a surrogate[7].

RESULTS

Patients characteristics

A total of 1,661 patients (11 cancer types) were included. The top three tumors were NSCLC (21.1%), melanoma (19.3%), and bladder cancer (12.9%), **Figure 1A**. Of all samples, 488 (29.4%) harbored a TMB of ≥ 10 mut/Mb, **Figure 1B**. The ICI type received was anti-PD-(L)1 in 76.6% cases, anti-CTLA-4 in 8.6%, and ICI

combination in 14.8% of the cases, **Figure 1C**. After a maximum follow-up of 80 months, the median OS was 42 months for both TMB ≥ 10mut/Mb (95% CI 0.35 – 0.63) and TMB ≥ 20 mut/Mb (95% CI 0.42 - 0.56), and 15 months for TMB < 10 mut/Mb (95% CI 0.39 – 0.59), multivariate log-rank P < 0.005, **Figure 1D**. The HRs for death were HR 0.44 (95% CI 0.34 - 0.56) and 0.57 (95% CI 0.49 - 0.67) for TMB ≥ 20 mut/Mb and ≥ 10 mut/Mb, respectively (P < 0.005). No difference was observed in death risk between cohorts with TMB 10 mut/Mb or less and 1 mut/Mb or less (HR 0.96; 95% CI 0.74 – 1.24; P = 0.73).

Single gene alterations and implications for survival

Twenty-seven gene mutations with n > 5 patients exhibited a statistically significant correlation with OS after ICI treatment when only tumors with TMB ≥ 10 mut/Mb were analyzed. Among them, 5 showed reduced OS on ICI: *STK11, KEAP1, CIC, E2F3*, and *TP53* (P < 0.05). In addition, 22 genes were associated with better OS: *NTRK3, TERT, NOTCH3, RNF43, TET1, PTPRD, NCOA3, TENT5C, ZFHX3, RIT1, CCNE1, PPM1D, GATA2, ALK, DNMT1, PTPRT, MET, EPHA7, BCL6, SMO, CDK6*, and *MED12* (p < 0.05), **Table 1**.

Multivariate analysis of individual gene alterations in high TMB patients

Among the 27 genes exhibiting a correlation with OS ($P < 0.05$), multivariate analysis confirmed a correlation between mutations in *STK11* (N=40, HR 1.84 (95% CI, 1.14 - 2.97) and *E2F3* (N=14, HR 3.17 (95% CI, 1.58 - 6.38]) and worse survival ($P < 0.05$). Mutations in *NTRK* (N=57, HR 0.39 95% CI, 0.20 - 0.78), *PTPRD* (N=125, HR 0.67 95% CI, 0.45 - 0.99), *RNF43* (N=52, HR 0.42 95% CI, 0.2015 - 0.89), *TENT5C* (N=15, HR 0.14 95% CI, 0.02 - 0.98), *TET1* (N=55, HR 0.48 95% CI, 0.25 - 0.91), *and ZFHX3* (N= 91, HR 0.62 95% CI, 0.39 - 0.99) were associated with better OS. When evaluated concurrently with the mutational profile, histology did not play a relevant role in the ICI response, except for melanoma, which endowed patients with better OS ($P < 0.05$). In addition, MSI status, age, and gender did not have a statistically significant effect on OS, **Figure 2**.

DISCUSSION

Despite prior data demonstrating that higher TMB correlates with responses to ICIs, the use of TMB as a predictive biomarker for OS still has limitations[3]. Only a non-significant difference in 3-year OS was noted between the TMB-high/low groups from Marabelle et al.[2], and more than half of the patients died regardless of TMB status at the 3-months landmark. Here, we show that not only high TMB but also its combination with somatic

mutational profile in some specific genes can be a predictor of survival benefit from ICI treatment.

The complexity of antitumor immune response reflexes in the absence of a universal biomarker to predict survival benefit from ICI[8] and an integrative analysis of clinical and molecular variables may guide better patient selection for ICI treatment[9,10]. Notably, we identified two mutated genes related to poor survival: *STK11* and *E2F3*. Interestingly, there is stronger evidence supporting the STK11-related ICI resistance[11]. In accordance, the cell-cycle promoter *E2F3* is a well described tumoral poor prognosis factor, and associated with a low immune signature score when amplified[12].

The multivariate analysis with the genes correlated to OS benefit did not find any clinical feature, except for melanoma histology (19.3% of samples studied) that could interfere with survival outcomes after ICI. This melanoma enrichment could justify a lack of correlation to MSI status as previous data shows the opposite[13].

LIMITATIONS

Our study has limitations, including its retrospective nature based on clinical and molecular data available in a public online database and a bias toward hypermutated tumors (NSCLC, melanoma, and urothelial carcinoma)[13], which could

explain the higher proportion of samples with TMB ≥ 10 (N 488, 29.4%). In addition, we used mutation in DNA repair genes to define MSI[7], not being able to state that all these patients have microsatellite instability phenotypes.

CONCLUSION

With this pan-cancer analysis, we: i) demonstrated that not only high TMB, but also its combination with somatic mutational profile in some specific genes can be a predictor of survival benefit from ICI treatment; ii) confirmed the 10 mut/Mb TMB cutoff as a positive predictive biomarker for ICI treatment. Although prospective trials are still needed, combining information of TMB and mutation profiles in some cancer genes can be decisive in better qualify patients for ICI treatment.

FIGURE LEGENDS

Figure 1. Patients' characteristics (n=1,661) and survival on ICIs according to TMB cut-offs A) Cancer types included. B) Number of samples per TMB cut-offs (<10 or >=10) and TMB (violin and boxplot) distribution. C) Type of ICI treatments used by patients. D) Effect of mutational load on overall survival after ICI treatment. Kaplan–Meier (KM) curves for patients with tumors within each TMB predefined cutoff. Overall survival is from the first dose of ICI. Median OS was 42 months for both TMB ≥

20mut/Mb (95% CI 0.35 – 0.63) and TMB ≥ 10 mut/Mb (95% CI 0.42 – 0.56), and 15 months for TMB < 10 mut/Mb (95% CI 0.39 – 0.59), multivariate log-rank P < 0.005.

Table 1. Single gene alterations and implications for survival.

Figure 2. Patients treated with ICI and with tumors presenting TMB ≥ 10 mut/Mb can be further stratified by their somatic mutation profile. A) Overall survival (OS) according to STK11 mutational status. B) OS according to TET1 mutational status. C) Forest plot for OS in multivariate analysis for 8 genes with N of at least 5 patients exhibiting a possible correlation with survival considering a standard alfa-error level (P < 0.05). Stratification variables included TMB under or above the median of 20 mut/Mb, sex, median age, microsatellite instability (MSI) status, and tumor types (non-small cell lung cancer (NSCLC), melanoma, bladder cancer, and colorectal cancer).

REFERENCES

1. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet*. 2019;51(2):202-206.
2. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective

biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol*. 2020;21(10):1353-1365.

3. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. *Cancer Cell*. 2021;39(2):154-173.

4. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6(269):l1.

5. Davidson-Pilon C. lifelines: survival analysis in Python. *J Open Source Softw*. 2019;4(40):1317.

6. Dos Santos, Felipe RC, et al. "Reboot: a straightforward approach to identify genes and splicing isoforms associated with cancer patient prognosis." NAR cancer 3.2 (2021): zcab024.

7. Yamamoto H, Imai K. Microsatellite instability: an update. *Arch Toxicol*. 2015;89(6):899-921.

8. Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann Oncol*. 2019;30(1):44-56.

9. Alban TJ, Chan TA. Immunotherapy biomarkers: the long and winding road. *Nat Rev Clin Oncol*. 2021;18(6):323-324.

10. Litchfield K, Reading JL, Puttick C, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. *Cell*. 2021;184(3):596-614.e14.

11. Krishnamurthy N, Goodman AM, Barkauskas DA, Kurzrock R. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. *Eur J Cancer*. 2021;148:215-229.

12. Wu L, Wan S, Li J, et al. Expression and prognostic value of E2F3 transcription factor in non-small cell lung cancer. *Oncol Lett*. 2021;21(5):411.

13. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. *N Engl J Med*. 2017;377(25):2500-2501.


A
CANCER TYPES
12.9%
Bladder Cancer
9.1% Renal Cell Carcinoma
2.6% Breast Cancer
5.4% Others
6.6% Colonrectal Cancer
21.1%
NSCLC
7.6% Esophagogastric Cancer
7% Glioma
8.4% Head and Neck Cancer
19.3%
Melanoma
B
SAMPLES
1200
900
600
300
0
1173
(70.6%)
488
(29.4%)
⩾ 10
< 10
TMB
TMB (mut/Mb)
< 10
⩾ 10
0
20
40
60
80
C
ICI TREATMENTS
76.6%
PD-(L)-1
8.6%
CTLA4
14.8%
Combination
D
OVERALL SURVIVAL
1.0
0.8
0.6
0.4
0.2
1 | TMB >= 20 (169/238)
2 | TMB >= 10 (307/488)
3 | TMB < 10 (522/1173)
0
10
20
30
40
50
60
70
80
Months
1 | TMB >= 20 (169/238)
At risk 236 154 81 34 13 4 4 3 0
Censored 1 47 101 140 159 165 165 166 169
Events 1 37 56 64 66 69 69 69 69
2 | TMB >= 10 (307/488)
At risk 481 281 141 66 31 11 9 4 0
Censored 2 85 188 252 283 298 298 303 307
Events 5 122 159 170 174 179 181 181 181
3 | TMB < 10 (522/1173)
At risk 1149 556 258 109 46 19 4 1 0
Censored 7 180 333 436 485 506 519 521 522
Events 17 437 582 628 642 648 650 651 651


A
STK11: Wild-type
STK11: Mutated
Overall survival probability
1.00
0.75
0.50
0.25
0.00
p < 0.0001
0
20
40
60
80
Follow up (months)
Number at risk
448 147 35 10 2
40 5 2 0 0
B
TET1: Wild-Type
TET1: Mutated
Overall survival probability
1.00
0.75
0.50
0.25
0.00
p = 0.0052
0
20
40
60
80
Follow up (months)
Number at risk
433 131 34 8 2
55 21 3 2 0
C
E2F3 (N=14)
STK11 (N=40)
NTRK3 (N=57)
PTPRD (N=125)
RNF43 (N=52)
TENT5C (N=15)
TET1 (N=55)
ZFHX3 (N=91)
Mutation
Male (N=308)
MSI (N=142)
Age > 66 (N=230)
TMB > 20 (N=238)
Melanoma (N=152)
NSCLC (N=115)
Bladder (N=89)
Colorectal (N=46)
Hazard Ratio (HR)
HR>1: increased risk
HR<1: smaller risk

Table 1. Single gene alterations and implications for survival.

	Better overall survival-related mutated genes	Worse overall survival-related mutated genes
TMB ≥ 10 mut/Mb (P < 0.05)	*NTRK3, TERT, NOTCH3, RNF43, TET1, PTPRD, NCOA3, TENT5C, ZFHX3, RIT1, CCNE1, PPM1D, GATA2, ALK, DNMT1, PTPRT, MET, EPHA7, BCL6, SMO, CDK6, MED12*	*STK11, KEAP1, CIC, E2F3, TP53*